INTERCEPT: Identifying and Managing Cancer Treatment Cardiotoxicities in Patients Undergoing Therapy- Enduring
Learning Objectives
Review recent data on cytotoxic chemotherapies, targeted therapies, and immunotherapies known to cause cardiotoxicity in cancer patients
Discuss the use of clinical tools, imaging, and other tests to evaluate patients at risk for cardiotoxicity before, during, and after cancer treatment
Employ multidisciplinary strategies to mitigate the risk for cardiotoxicity in cancer patients.
Available Credit
- 1.00 ACPE - Pharmacist
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 ANCC
- 1.00 Attendance
- 1.00 JA Credit - AH
- 1.00 Approved for AMA PRA Category 1 Credit(s)™